Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia

Ahmed Awais, Constantine S. Tam, Dimitrios Kontoyiannis, Alessandra Ferrajoli, Madeleine Duvic, Jorge Cortes, Michael J. Keating

Research output: Contribution to journalArticle

Abstract

The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies. However, its potential role in augmenting immune reactions against opportunistic infections has not been explored. We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic leukemia.

Original languageEnglish (US)
Pages (from-to)e69-e71
JournalClinical Infectious Diseases
Volume46
Issue number7
DOIs
StatePublished - Apr 1 2008
Externally publishedYes

Fingerprint

Mycobacterium marinum
B-Cell Chronic Lymphocytic Leukemia
Skin
Opportunistic Infections
Hematologic Neoplasms
Infection
Antineoplastic Agents
Therapeutics
Pharmaceutical Preparations
lenalidomide

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. / Awais, Ahmed; Tam, Constantine S.; Kontoyiannis, Dimitrios; Ferrajoli, Alessandra; Duvic, Madeleine; Cortes, Jorge; Keating, Michael J.

In: Clinical Infectious Diseases, Vol. 46, No. 7, 01.04.2008, p. e69-e71.

Research output: Contribution to journalArticle

Awais, Ahmed ; Tam, Constantine S. ; Kontoyiannis, Dimitrios ; Ferrajoli, Alessandra ; Duvic, Madeleine ; Cortes, Jorge ; Keating, Michael J. / Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. In: Clinical Infectious Diseases. 2008 ; Vol. 46, No. 7. pp. e69-e71.
@article{243553ecbe1f487fb8b2b9f37c9b78c9,
title = "Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia",
abstract = "The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies. However, its potential role in augmenting immune reactions against opportunistic infections has not been explored. We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic leukemia.",
author = "Ahmed Awais and Tam, {Constantine S.} and Dimitrios Kontoyiannis and Alessandra Ferrajoli and Madeleine Duvic and Jorge Cortes and Keating, {Michael J.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1086/529388",
language = "English (US)",
volume = "46",
pages = "e69--e71",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia

AU - Awais, Ahmed

AU - Tam, Constantine S.

AU - Kontoyiannis, Dimitrios

AU - Ferrajoli, Alessandra

AU - Duvic, Madeleine

AU - Cortes, Jorge

AU - Keating, Michael J.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies. However, its potential role in augmenting immune reactions against opportunistic infections has not been explored. We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic leukemia.

AB - The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies. However, its potential role in augmenting immune reactions against opportunistic infections has not been explored. We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic leukemia.

UR - http://www.scopus.com/inward/record.url?scp=42549115862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549115862&partnerID=8YFLogxK

U2 - 10.1086/529388

DO - 10.1086/529388

M3 - Article

C2 - 18444808

AN - SCOPUS:42549115862

VL - 46

SP - e69-e71

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 7

ER -